Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| German Oncology Center, Cyprus | OTHER |
| Bank of Cyprus Oncology Center BOCOC | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Aim: To evaluate the effectiveness of thymus honey on radiation induced-oral mucositis and xerostomia.
Background: Oral mucositis and xerostomia are two of the most severe side effects that head and neck cancer patients confront during and after the completion of radiotherapy. Although several medications are used for their treatment, these fail to provide a fully effective and comprehensive management. Honey and thyme have been studied for the management of various treatment-related side effects.
Design: Α double blinded randomised controlled trial will be used for this study.
Methods: 200 head and neck cancer patients who receive radiotherapy will be included in this study. Patients will be randomised and divided into two equal groups of 100 participants; the intervention group (oral spray with thyme and honey + standard care) and the control group ( placebo spray + standard care). Assessments with xerostomia and oral mucositis scales additionally to 4 self-administered questionnaires will occur in both groups at baseline and then weekly and 6 months following completion of treatment. The duration of the study will be 3 years from the day of approval of this research protocol.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Thyme and Honey-based oral spray | Experimental | Thyme and Honey-based oral spray |
|
| Placebo oral spray | Placebo Comparator | Placebo oral spray |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Thyme and Honey-based oral spray | Dietary Supplement | 4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in Mucositis Grade (RTOG) at weekly assessments | The scale includes 5 grades (from 0 to IV). Higher grade denotes more severe mucositis | Baseline (week 4), week 5, week 6, week 7, week 8 and week 24 |
| Change from baseline in Xerostomia Grade (CTCAE) at weekly assessments | he scale includes 5 grades (from 0 to IV). Higher grade denotes more severe xerostomia | Baseline (week 4), week 5, week 6, week 7, week 8 and week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in Xerostomia Questionnaire (Dirix et al) | consists of three parts. In the first part, patients rate on a 4-likert scale (0, 1, 2, 3) the intensity of xerostomia, oral pain, taste, and dysphagia they experience and whether they suffered from more intense tooth decay or other related problems. Secondly, patients evaluate the impact of xerostomia on their Quality of Life. The Quality of Life (QoL) scales contains 15 items (ranging from 1 to 5) with a higher score indicating a worst QoL level (minimum score is 15 and the maximum is 75). Finally, patients rate the degree to which they suffered from xerostomia on a 100-mm Visual Analogue Scale (VAS). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andreas Charalambous, PhD | Contact | 25002011 | andreas.charalambous@cut.ac.cy |
| Name | Affiliation | Role |
|---|---|---|
| Andreas Charalambous, PhD | Cyprus University of Technology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| German Oncology Center | Recruiting | Limassol | 4108 | Cyprus |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33741726 | Background | Thrasyvoulou S, Tsitsi T, Katodritis N, Vomvas D, Charalambous M, Charalambous A. Reliability and Validity of the Greek Version of the Oral Mucositis Weekly Questionnaire in the Head and Neck Cancer Context. J Nurs Meas. 2021 Aug 1;29(2):317-333. doi: 10.1891/JNM-D-19-00096. Epub 2021 Mar 19. | |
| 24877858 | Background |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| D014987 | Xerostomia |
| D013280 | Stomatitis |
| D011832 | Radiation Injuries |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D012466 | Salivary Gland Diseases |
| D009059 | Mouth Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo oral spray | Dietary Supplement | 4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session |
|
| Baseline, on completion of radiotherapy, 4 weeks and 24 weeks after radiotherapy |
| Change from baseline in Oral Mucositis Questionnaire (OMWQ) | The 12-item questionnaire is designed to evaluate the overall wellbeing of the patient relating to OM during the last week. Possible answers are scored on Likert scales containing 5, 7 and 11 points. The first 2 questions assess global health and quality of life (QOL). The questions are rated on a 7-point scale, with 1 indicating very poor and 7 indicating excellent. The fourth question, which is made up of 6 items, addresses the impact of MTS on patient function and includes a 5-point scale, with 0 indicating not limited and 4 indicating unable to do. The remaining 3 questions assess the degree of mouth and throat pain and soreness using an 11-point scale, with 0 indicating no pain or soreness and 10 indicating the worst pain or soreness imaginable or possible. | Baseline, on completion of radiotherapy, 4 weeks and 24 weeks after radiotherapy |
| Change from baseline in health-related QoL (EORTC QLQ-C30) questionnaire | The EORTC QLQ-C30 is a cancer-specific self-report questionnaire and comprises a global QOL scale (two items), five functional scales, three symptom scales and six single items. Scores QLQ-C30 are linearly transformed to a scale of 0-100, with a higher score indicating a better level of functioning or global QOL, or a worse level of symptoms or problems | Baseline, on completion of radiotherapy, 4 weeks and 24 weeks after radiotherapy |
| Change from baseline in health-related QoL (EORTC QLQ-H&N43) questionnaire | The EORTC QLQ-H&N35 module covers specific head and neck issues, comprises ten single items and seven subscales: swallowing, senses, speech, social eating, social contact and sexuality. QLQ-H&N35 are linearly transformed to a scale of 0-100, with a higher score indicating a better level of functioning or global QOL, or a worse level of symptoms or problem. | Baseline, on completion of radiotherapy, 4 weeks and 24 weeks after radiotherapy |
| Bank of Cyprus Oncology Center | Not yet recruiting | Nicosia | 2006 | Cyprus |
|
| Charalambous A. Hermeneutic phenomenological interpretations of patients with head and neck neoplasm experiences living with radiation-induced xerostomia: the price to pay? Eur J Oncol Nurs. 2014 Oct;18(5):512-20. doi: 10.1016/j.ejon.2014.04.007. Epub 2014 May 27. |
| 29784145 | Result | Charalambous M, Raftopoulos V, Paikousis L, Katodritis N, Lambrinou E, Vomvas D, Georgiou M, Charalambous A. The effect of the use of thyme honey in minimizing radiation - induced oral mucositis in head and neck cancer patients: A randomized controlled trial. Eur J Oncol Nurs. 2018 Jun;34:89-97. doi: 10.1016/j.ejon.2018.04.003. Epub 2018 Apr 30. |
| 28279391 | Result | Charalambous A, Lambrinou E, Katodritis N, Vomvas D, Raftopoulos V, Georgiou M, Paikousis L, Charalambous M. The effectiveness of thyme honey for the management of treatment-induced xerostomia in head and neck cancer patients: A feasibility randomized control trial. Eur J Oncol Nurs. 2017 Apr;27:1-8. doi: 10.1016/j.ejon.2017.01.001. Epub 2017 Jan 16. |
| D009057 |
| Stomatognathic Diseases |
| D014947 | Wounds and Injuries |